

Innovation all for the patients



Roche A member of the Roche group

## Chugai Reorganizes Business Operation in China to Further Strengthen the Foundation of Overseas Business


- Integrate and reorganize two group companies in China to strengthen governance, improve organizational efficiency, and enhance individual functions
- Strengthen the foundation of business by newly establishing functions for early clinical development and building a streamlined value chain throughout clinical development to marketing

TOKYO, February 14, 2022 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced reorganization plans regarding business operations in China to further strengthen the foundation of overseas business. Among its group companies in China, Chugai Pharma Science (Beijing) Co., Ltd. and Chugai Pharma China Co., Ltd. will be integrated to strengthen governance, improve organizational structure, and enhance individual functions in China.

“Our mission is to dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world. The reorganization aims to swiftly deliver innovation to the many patients in China who are awaiting new treatments, by building a streamlined value chain through early clinical development to marketing,” said Chugai’s President and CEO, Dr. Osamu Okuda. “Chugai aims to become a top innovator in 2030, and ‘Expectation from patients all over the world’ is one of the perspectives on what it means to achieve the goal. We will continue to thoroughly pursuing innovation and strengthening the business foundation.”

The reorganization aims to ensure efficient business operations by optimizing overlapping functions. It also intends to strengthen the foundation of business in China and accelerate cross-divisional collaboration, by newly establishing functions for early clinical development and building a streamlined value chain throughout clinical development to marketing. Also, in order to enhance governance and compliance, Quality & Regulatory Compliance Department will be implemented independently from other divisions to oversee and supervise regulatory management functions in each division.

[Reference] Business structure after reorganization



<Overview of the integrated company>

Company name: Chugai Pharma China Co., Ltd.

Location: Building G31, No. 801 Jiankang Dadao, Medical City Taizhou, Jiangsu 225300

Capital: 30 million USD (100% owned by Chugai)

Activities: Research, development and transfer of pharmaceutical technology; clinical development, regulatory affairs, import, marketing and provision of information for pharmaceutical products in China

Representative: Kunihiko Yukimatsu (President of current Chugai Pharma China Co., Ltd.)

Number of employees: 178

###